New research from the Cardano Foundation reveals that having a large reserve of tokens is not enough to ensure the long-term security of proof-of-stake blockchains. The study introduces a state-dependent reserve threshold that categorizes network security into three states: complete failure, reserve-dependent security, and fee-only security. It highlights that market volatility can affect security despite substantial reserves, and the way rewards are drawn from reserves (percentage-based vs fixed payouts) impacts sustainability. This framework helps investors and protocols better assess security risks beyond just reserve size.
Cardano Foundation's research on proof-of-stake security is presented here with Pluang's market data for context. As of Oct 13, 2026 20:51 WIB, out of 50 major cryptocurrencies on Pluang, 7 rose and 42 fell. Notable price changes include BAL (Balancer) at Rp16.297 with an 11.14% increase, ONE (Harmony) at Rp31 down 9.13% with 83% sell order activity, and EOS (EOS.IO) at Rp12.649 up 8.13%.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
